

Remarks

Applicant herewith submits an amendment to the specification to identify the deposit of the hybridoma cell line which produces SN6j antibodies of the presently claimed method. As required under 37 CFR 1.809(d), the amendment identifies the ATCC accession number for the deposit of the cell line Y4-2F1 (also referred to in the specification as originally filed as SN6j), the date of the deposit, the name and address of the repository, and a description of the deposited biological material as a murine hybridoma. Applicant also herewith submits a copy of a letter from the ATCC Patent Depository (Exhibit A) acknowledging deposit of the Y4-2F1 cell line (among others) and assigning deposit no. ATCC HB-2171 to the Y4-2F1 hybridoma cell line.

Conclusion

Based on the above argument and amendment, Applicant believes that claims 1, 5-7, and 9-13 are now in a condition for allowance and therefore respectfully request the Examiner to allow these claims.

It is believed no fee is due with this communication. If however, that is incorrect, any fee due may be charged to Deposit Account No. 08-2442.

Respectfully submitted,
HODGSON RUSS LLP

By 
John D. Lopinski, Ph.D., Reg. No. 50,846

Hodgson Russ LLP
One M&T Plaza, Suite 2000
Buffalo, New York 14203-2391
(716) 848-1628
Dated: March 10, 2006